103 related articles for article (PubMed ID: 7741767)
21. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis.
Smee DF; Hurst BL; Day CW
Antivir Chem Chemother; 2012 Aug; 22(6):263-72. PubMed ID: 22516927
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine.
Thomson TA; Spinella-Jaegle S; Francesconi E; Meakin C; Millet S; Flao KL; Hidden H; Ruuth E
Scand J Immunol; 2002 Jul; 56(1):35-42. PubMed ID: 12100469
[TBL] [Abstract][Full Text] [Related]
23. Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase.
Ittarat I; Asawamahasakda W; Bartlett MS; Smith JW; Meshnick SR
Antimicrob Agents Chemother; 1995 Feb; 39(2):325-8. PubMed ID: 7726490
[TBL] [Abstract][Full Text] [Related]
24. Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans.
Zameitat E; Gojković Z; Knecht W; Piskur J; Löffler M
FEBS J; 2006 Jul; 273(14):3183-91. PubMed ID: 16774642
[TBL] [Abstract][Full Text] [Related]
25. Drosophila melanogaster dihydroorotate dehydrogenase: the N-terminus is important for biological function in vivo but not for catalytic properties in vitro.
Löffler M; Knecht W; Rawls J; Ullrich A; Dietz C
Insect Biochem Mol Biol; 2002 Sep; 32(9):1159-69. PubMed ID: 12213251
[TBL] [Abstract][Full Text] [Related]
26. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.
de Kant E; Pinedo HM; Laurensse E; Peters GJ
Cancer Lett; 1989 Jul; 46(2):123-7. PubMed ID: 2546667
[TBL] [Abstract][Full Text] [Related]
27. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
28. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
29. Histidine to alanine mutants of human dihydroorotate dehydrogenase. Identification of a brequinar-resistant mutant enzyme.
Davis JP; Copeland RA
Biochem Pharmacol; 1997 Aug; 54(4):459-65. PubMed ID: 9313772
[TBL] [Abstract][Full Text] [Related]
30. Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects?
Ullrich A; Knecht W; Fries M; Löffler M
Eur J Biochem; 2001 Mar; 268(6):1861-8. PubMed ID: 11248707
[TBL] [Abstract][Full Text] [Related]
31. dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess.
Seymour KK; Yeo AE; Rieckmann KH; Christopherson RI
Ann Trop Med Parasitol; 1997 Sep; 91(6):603-9. PubMed ID: 9425362
[TBL] [Abstract][Full Text] [Related]
32. Cellular pharmacology of DUP-785, a new anticancer agent.
Anderson LW; Strong JM; Cysyk RL
Cancer Commun; 1989; 1(6):381-7. PubMed ID: 2562006
[TBL] [Abstract][Full Text] [Related]
33. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationship of a pyrimidine receptor in the rat isolated superior cervical ganglion.
Connolly GP; Harrison PJ
Br J Pharmacol; 1995 Nov; 116(6):2764-70. PubMed ID: 8591002
[TBL] [Abstract][Full Text] [Related]
35. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.
Williamson RA; Yea CM; Robson PA; Curnock AP; Gadher S; Hambleton AB; Woodward K; Bruneau JM; Hambleton P; Moss D; Thomson TA; Spinella-Jaegle S; Morand P; Courtin O; Sautés C; Westwood R; Hercend T; Kuo EA; Ruuth E
J Biol Chem; 1995 Sep; 270(38):22467-72. PubMed ID: 7673235
[TBL] [Abstract][Full Text] [Related]
36. Dihydroorotate dehydrogenase. Profile of a novel target for antiproliferative and immunosuppressive drugs.
Löffler M; Grein K; Knecht W; Klein A; Bergjohann U
Adv Exp Med Biol; 1998; 431():507-13. PubMed ID: 9598119
[No Abstract] [Full Text] [Related]
37. Biosynthesis and scavenging of pyrimidines by pathogenic mycobacteria.
Wheeler PR
J Gen Microbiol; 1990 Jan; 136(1):189-201. PubMed ID: 2191077
[TBL] [Abstract][Full Text] [Related]
38. Evidence for transformation-related increase in CTP synthetase activity in situ in human lymphoblastic leukemia.
van den Berg AA; van Lenthe H; Busch S; de Korte D; Roos D; van Kuilenburg AB; van Gennip AH
Eur J Biochem; 1993 Aug; 216(1):161-7. PubMed ID: 8365402
[TBL] [Abstract][Full Text] [Related]
39. Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis.
Kobayashi K; Nakashima A; Nagata H; Nakajima H; Yamaguchi K; Sato S; Miki I
Inflamm Res; 2001 Jan; 50(1):24-31. PubMed ID: 11235018
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro.
Hammond DJ; Burchell JR; Pudney M
Mol Biochem Parasitol; 1985 Jan; 14(1):97-109. PubMed ID: 3885032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
